SYNCROSOME is proud to announce that it has joined the ETAP-Lab group
SYNCROSOME is proud to announce that it has joined the ETAP-Lab group – an offshoot of the preclinical CRO ETAP-Lab. 🚀 This acquisition ...
10 octobre, 2023 Syncrosome News
Arterial Hypertension
Pulmonary Arterial Hypertension
Myocardial Ischemia
Heart Failure
Blood loss
Parkinson’s Disease (PD)
Stroke
Brain Blood Barrier Passage
Irritable Bowel Syndrome
Inflammatory Bowel Disease
Ulcer
Emesis & Nausea
Gastric Emptying
Intestinal Transit
Type 1 diabetes
Type 2 diabetes
Asthma
COPD
Cough
As an innovative preclinical CRO with relevant disease models we offer robust drug efficacy data and high value interpretation to assist drug discovery companies in evaluating the potential of their therapeutic compounds.
HIGH CONTENT EFFICACY DATA
PHYSIOLOGICAL BIOMARKERS
FUNCTIONAL EXPLORATION
CELLULAR, MOLECULAR AND INFLAMMATORY BIOMAKERS
IN VIVO EXPERIMENTS
RESOURCES CENTER
15
DISEASE MODELS
130
CUSTOMERS
40
TECHNICAL DATA SHEETS
Download Disease models, Technical sheets, …
THEY TRUST US
LATEST NEWS
Intracerebral administration in rat and mouse
If you need to perform intracerebral administration of your test compound, SYNCROSOME provides stereotaxic surgery in rats and mice to perform acute o...
21 août, 2023 Central Nervous SystemNew cardiovascular model available at SYNCROSOME
Collaboration with VASA Therapeutics : characterization a heart failure model with preserved ejection fraction (HFpEF) / Dahl salt sensitive rats. Dow...
06 février, 2023 CardiovascularNEWS for CNS Department
Nose-to-brain delivery allows application of drugs at the roof of the nasal cavity, which are transported to the central nervous system (CNS) of human...
03 octobre, 2022 Central Nervous System